ITACA-S study was designed to evaluate whether a sequential treatment of FOLFIRI -LSB- irinotecan plus @-fluorouracil/folinic acid ( @-FU/LV ) -RSB- followed by docetaxel plus cisplatin improves disease-free survival in comparison with @-FU/LV in patients with radically resected gastric cancer .